MedTrace Logo

Tacrolimus Adjustment by NFAT-related Gene Expression in Lung Allograft Recipients.

NCT02278952 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2019-12-03

Study results available
· View outcomes & findings →

Summary

This is a non-interventional cohort study to assess a novel assay to detect excessive or insufficient immunosuppression from the drug tacrolimus in lung transplant recipients. The assay measures mean residual expression (MRE) of genes downstream of nuclear factor of activated T cells (NFAT), a transcription factor regulated by tacrolimus. The investigators will assess whether MRE levels identify subjects at risk for rejection (insufficient immunosuppression) or infection (excessive immunosuppression).

Conditions

  • Transplantation, Lung

Sponsors & Collaborators

Principal Investigators

  • Greenland John, MD, PhD · University of California, San Francisco

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-05-31
Completion
2018-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02278952 on ClinicalTrials.gov